Skip to main content
. 2024 Dec 12;19(12):e0315287. doi: 10.1371/journal.pone.0315287

Fig 3.

Fig 3

Meta-analysis showing, among HER2-negative cases (IHC 0, 1+, and 2+/ISH), the prevalence of HER2- zero (a), and HER2-low expressing tumors (b).